ESTRO 2024 - Abstract Book

S858

Clinical - CNS

ESTRO 2024

treatment compared to the VMAT one with median[range] of mean doses of 12.5[12.0-23.0]Gy for the VMAT, and 0.6[0.2-1.0]Gy and 0.9[0.3-1.5]Gy for 90Y treatment assuming A95% and A99%, respectively.

Conclusion:

Our results suggest that IACI 90Y-PVA-MBs might deliver higher doses to tumors and lower doses to the non-target volumes compared with the VMAT approach. The simulation using MRI-3DT1-w seems a promising and feasible approach to plan the endovascular treatment.

Keywords: 90Y-Microbubbles, glioblastoma, cerebral infusion

1726

Digital Poster

NEUROPATHIC PAIN TREATMENT FOR NEURALGIA TRIGEMINAL. THE RADIOSURGERY OPTION

Lorena Draghini, Sara Costantini, Michelina Casale, Paola Anselmo, Fabio Arcidiacono, Alessandro Di Marzo, Sara Terenzi, Marco Muti, Matteo Marconi, Marco Italiani, Fabio Trippa

Radiation Oncology Centre, S.Maria Hospital, Terni, Italy

Purpose/Objective:

To evaluate the efficacy and safety of radiosurgery (RS) for patients with drugs resistant neuropathic pain for neuralgia trigeminal.

Material/Methods:

From august 2008 to February 2023 41 patients were treated with SRS for drug resistant neuralgia trigeminal. Radiosurgery was given with photon beam multiple arc therapy in a single fraction by linear accelerator with micro multileafs collimator. Diagnostic MRI was co-registered with CT plan to delineate target volume and elaborate treatment plan. Three patients were lost to follow-up, 38 were evaluable. Clinical response to treatment was considered as complete or partial response, that is if pain was gone or reduced and patient stopped taking or reduced drugs, respectively. Clinical stability or progression was defined if pain was stable or progressed. Statistical analysis was performed with Kaplan-Meyer method. Acute and late toxicity was scored with CTAEC scale.

Results:

Median age was 66 years (range, 32-88), median KPS 90% (range, 80-100%), median PTV was < 0.1 cc, left side in 17 patients, right side in 24, median RS dose 70 Gy (range, 40-75). Six patients had neurovascular conflict and two of